DOW

Dow is a deep-cyclical commodity chemicals maker caught in a multi-year down-cycle, and the FY2025 10-K shows the trough is biting hard. Net sales fell 7% to $40.0B with declines across all three segments and every geography, driven entirely by a 7% drop in local price as volume was merely flat. That extends a brutal top-line slide from $56.9B in FY2022 to $40.0B in FY2025. Profitability went with it: the company swung to a net loss of -$2.44B (from +$1.20B in FY2024), with $1,856M of restructuring, goodwill impairment ($690M in Polyurethanes & Construction Chemicals) and asset charges, plus equity losses at its principal joint ventures from integrated margin compression. Gross margin is just 13.0%, net margin -6.1%, and ROE -15.3%.

The cash picture is the most pressing concern. Operating cash flow collapsed 64.6% to $1.03B, yet Dow paid $1.49B in dividends in FY2025 — the payout now exceeds cash generated from operations and is being funded by the balance sheet, while buybacks were cut to zero. Cash rose to $3.82B (up 74.3%), but that is partly a function of the InfraPark sale of 49% of Diamond Infrastructure Solutions and the DowAksa divestiture rather than operating strength. With ~$15.1B long-term debt against $16.0B equity and capex still at $2.48B, the free-cash-flow math leaves little cushion if pricing stays depressed, raising real risk to the dividend.